• Print

Laccure AB has developed a new product for the treatment and prevention of Bacterial Vaginosis (BV) to meet women’s requirements with regards to efficacy, safety and user-friendliness.

Laccure’s novel, antibiotic-free vaginal tablet has been tested in randomized, controlled clinical multicenter studies including 126 women. The results show a cure rate of 80 percent following a single administration of one (1) vaginal tablet. Along with a good safety profile and by fully meeting women’s need for user-friendly comfort, this represents a major improvement in the treatment of BV.

The product is based on a patented substance that releases lactic acid over time to re-adjust vaginal acidity to healthy levels. It only needs to be dosed once to effectively treat bacterial vaginosis, and then once a month to prevent recurrence.


Bacterial Vaginosis

It is estimated that more than 300 million women throughout the world suffer from bacterial vaginosis every year however, there are currently no other effective and safe products available that are also user-friendly. Odorous vaginal discharge is the most common symptom among women with bacterial vaginosis making this a serious quality of life problem for affected women.

Bacterial Vaginosis (BV) is caused by an imbalance in the naturally occurring bacterial flora of the vaginal mucosa resulting in increased vaginal alkalinity (too high pH), inhibition of the normal lactobacilli growth and discharge with a strong foul fishy odour. It is the most common type of gynaecologic infection and accounts for about half of all vaginal infections. BV has a prevalence of 10-30 % in the developed countries. It often recurs several times per year and many women suffer in silence with these symptoms (international market survey of 2600 women, data on file). Today ‘s treatment consists of antibiotics and short-acting, difficult-to-use pH lowering products.